Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, migraine, addiction, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Teva, Morphosys and Takeda.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Nov 25, 2015
Teva and Heptares Enter Agreement to Discover and Develop Novel, Small-Molecule CGRP Antagonists for Treatment of Migraine
Oct 2, 2015
Heptares wins Best UK Biotech Dealmaker Award at OBN Annual Awards 2015

Dec 7-11, 2015
IBC’s 26th Annual Antibody Engineering and Therapeutics Meeting
San Diego, CA, USA
Presenting: Cath Hutchings

Jan 11-13, 2016
JPMorgan Healthcare Conference
San Francisco, CA, USA
Attending: Malcolm Weir, Dan Grau

© 2012-2015 Heptares Therapeutics